No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults

Documenti analoghi

• Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2024)
• Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
  di: Richard Bertz, et al.
  Pubblicazione: (2025)
• A Drug‐Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2‐ and MATE1‐Mediated Transport of Metformin in Healthy Participants
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2024)
• Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
  di: Rajinder Bhardwaj, et al.
  Pubblicazione: (2024)
• A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants
  di: Shichang Miao, et al.
  Pubblicazione: (2024)